TL;DR
A study published in Nature Medicine links lower NRF2 levels in oligodendrocytes—cells that maintain myelin—to abnormal myelin, loss of large nerve fibers and faster cognitive decline. Mouse experiments support a possible role for the pathway, but the research does not show that an NRF2-targeting drug prevents age-related decline in people.
Researchers from the University of Edinburgh and the UK Dementia Research Institute report that myelin-producing brain cells may become dysfunctional with age, potentially contributing to damage in nerve fibers and cognitive decline. In a study published in Nature Medicine, findings from older adults and experiments in mice point to reduced activity of the protective protein NRF2 in oligodendrocytes as a possible part of that process.
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The human research drew on the Lothian Birth Cohort 1936, whose members have had their cognitive abilities tracked from childhood into old age. Between ages 70 and 82, participants completed tests of memory, information-processing speed and spatial reasoning. Of 1,091 people enrolled, 866 completed additional testing after age 70; nearly all showed some decline, though the pace varied.
Researchers examined brain tissue collected after death from a subset of participants. People whose abilities had declined more quickly tended to have fewer large nerve fibers and abnormal accumulations of myelin, the insulating coating that helps electrical signals travel along nerve fibers. These tissue features were associated with the rate of decline over time, rather than cognitive test performance at one specific age.
The team then investigated oligodendrocytes, the cells that produce and maintain myelin. In the human tissue, more severe decline was associated with lower levels of NRF2 in these cells. In mice, researchers reduced NRF2 specifically in oligodendrocytes and observed excessive myelin, loss of large nerve fibers and weaker improvement in cognitive performance with age. The mouse work supports a possible causal role for the pathway, but it does not establish that the same intervention or a drug would prevent decline in people.
A Possible Target in Aging Brains
The findings could shift research attention toward how the brain’s support cells change with age, rather than focusing only on nerve cells themselves. If further work confirms that oligodendrocyte dysfunction contributes to nerve-fiber damage, preserving these cells’ normal function could become one avenue for studying ways to protect cognition.
The NRF2 pathway is already targeted by medicines used for other neurological conditions, including multiple sclerosis. That raises the possibility of studying existing drugs for a different purpose. However, the study does not show that any such medicine slows age-related cognitive decline, and no treatment recommendation follows from these findings. Establishing benefit and safety for older adults would require dedicated clinical research.
Products Worth Considering
Fitbit Versa 4 Health and Fitness Smartwatch with GPS, Heart Rate and Sleep Tracking, Alexa, Water Resistant, Black
Fitbit Charge 5 Health and Fitness Tracker with Built-In GPS, Stress Management, Sleep Tracking, and 24/7 Heart Rate Monitoring
Philips Sonicare 6500 Rechargeable Electric Toothbrush with 2 Brush Heads, White
As an affiliate, we earn on qualifying purchases.
From Human Tissue to Mouse Tests
The study combines long-term cognitive records with postmortem brain analysis and animal experiments. The cohort’s repeated assessments let researchers compare the pace of change across decades with features later seen in brain tissue. Such an association can identify patterns, but human tissue findings alone cannot show that one biological change caused another.
The mouse experiments provided a test of mechanism: reducing NRF2 in oligodendrocytes produced abnormalities resembling those found in the human samples. The authors also point to prior research in multiple sclerosis in which increasing NRF2 activity was associated with improved cognitive function. That background offers a rationale for further investigation, but multiple sclerosis treatment results cannot establish effectiveness for age-related decline.
““As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.””
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
Questions Before Any Treatment
The study does not establish whether reduced NRF2 activity begins the changes in human brains or arises alongside other age-related processes. The human findings are observational, and the tissue came from only a subset of cohort members. The mouse experiments strengthen the case for a biological link but cannot show that the pathway has the same effects in people.
It is also unclear whether medicines that affect NRF2 could safely and effectively preserve cognition in older adults, which patients might benefit, or when treatment would need to begin. The supplied study account does not identify a clinical trial testing an NRF2-targeting drug for age-related cognitive decline. Whether the findings can lead to a usable therapy remains unknown.
Testing the NRF2 Pathway
Further research will need to establish how NRF2 activity changes in aging human brains and whether modifying it can protect oligodendrocytes and nerve fibers without harmful effects. Researchers would also need to determine whether the abnormalities identified in tissue can be measured reliably in living people.
If preclinical work supports a treatment approach, clinical studies would have to test an NRF2-targeting medicine directly in older adults, measuring both cognitive outcomes and safety over time. Until then, the study offers a potential biological target for research, not evidence that existing medicines prevent or reverse age-related cognitive decline.
Key Questions
What brain cells are implicated in the study?
The research focused on oligodendrocytes, cells that produce and maintain myelin, the coating around nerve fibers.
What is NRF2?
NRF2 is a protein that regulates genes involved in cellular protection and normal function. The study associated lower NRF2 levels in oligodendrocytes with more severe cognitive decline.
Does the study prove that these cells cause cognitive decline in people?
No. The human results show associations between cognitive decline and brain-tissue changes. Mouse experiments offer evidence of a possible mechanism, but they do not prove causation in humans.
The study identifies a pathway targeted by medicines used for other conditions, but it does not test those medicines as treatments for age-related decline. Clinical studies would be needed to assess benefit and safety in older adults.
Source: rss
